Ocular Therapeutix, Inc. (OCUL) Stock Price, Financial Report, & Fundamental AnalysisNASDAQ:OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Ocular Therapeutix, Inc. Fundamental Analysis
OCUL has had growing revenue for the last 5 years
Net Income Growth
OCUL has had growing net income for the last 2 years
OCUL has positive revenue for last 5 years
Small market capitalization. Market capitalization is less than 2bn USD
Price to Book (PBV) Ratio
Overvalued price-to-book. OCUL stock price is overvalued by more than 2x the price-to-book value.
OCUL never has positive net income for 2 years.
Debt-Equity Ratio (DER)
OCUL debt is 2.43x it's equity.
OCUL has low dividend yield (0%).
Return of Assets
OCUL has low return of asset (-37.42%).
Return of Equity
OCUL has low return of equity (-84.83%).
Return of Invested Capital
OCUL has low ROIC.
Ocular Therapeutix, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- 43,522,000 USD
- 121,559,000 USD
- Net Income
- -6,553,000 USD
- Profit Margin
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -66,744,000 USD
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
Long Term Liabilities
|Dividend Payout Ratio (DPR)||0%|
|Dividend Payout Ratio (DPR)||0%|
|Dividend per Share||0,00 USD|
|Price to Earning (PER)||-2.6x|
|Price to Earning-Growth (PEG)||0x|
|Price to Book Value (PBV)||0x|
|Debt-Equity Ratio (DER)||243.03%|
|Net Profit Margin (NPM)||-119.35%|
|Return of Assets (ROA)||-37.42%|
|Return of Equity (ROE)||-84.83%|
|Return on Capital Employed (ROCE)||-59.81%|
|Days of Sales Outstanding (DSO)||145.35|
|Days of Inventory Outstanding (DIO)||121.64|
|Days Payable Outstanding (DPO)||417.91|
|Operating Cycle (OC)||157.48|
|Cash Conversion Cycle (CCC)||-242.56|
Ocular Therapeutix, Inc. Executives
- CEO Name
- Mr. Antony Mattessich
Ocular Therapeutix, Inc. Profile
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- Company name
- Ocular Therapeutix, Inc.
- NASDAQ Global Market
24 Crosby Dr